DARA BioSciences Spiking Higher after Positive Phase I Results
Today DARA BioSciences (Nasdaq: DARA) announced the positive results of a randomized, placebo-controlled, double-blind, escalating single-dose study to evaluate the safety, tolerability, pharmacokinetics and food effect of DB959Na in healthy male and female volunteers. The presentation provided details on the company's lead oral diabetes drug candidate DB959.
Read more here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.